ESTRO meets Asia 2024 - Abstract Book

S166

Interdisciplinary – Head & neck

ESTRO meets Asia 2024

(Figure 2.)

Conclusion:

Risk stratification based on dynamic assessment of both radiological and biological response markedly enhance prognostic insights and shed light on tailored treatment modifications in LA-NPCs.

Keywords: longitudinal EBV DNA, tumor regression

72

Digital Poster

Meta-analysis of targeted therapy for recurrence or metastasis adenoid cystic carcinoma

Lu Zhang 1,2 , Jiang-Dong Sui 1 , Hao-nan Yang 1,3,4 , Ying Wang 1 , Dan Li 1 , Zheng Lei 1,2 , Mengqi Yang 1 , Yun-Chang Liu 1,2 , Jiang He 1,4 , Yong-Zhong Wu 1 1 Radiation Oncology Center, Chongqing University Cancer Hospital, Chongqing, China. 2 College of Medicine, Chongqing University, Chongqing, China. 3 College of Medicine, Chongqing University Cancer Hospital, Chongqing, China. 4 College of Bioengineering, Chongqing University, Chongqing, China

Purpose/Objective:

Several clinical studies have demonstrated the potential of molecular-targeted agents for the treatment of recurrent or metastatic adenoid cystic carcinoma (R/M ACC). However, there is currently no consensus regarding the efficacy of molecular-targeted agents for patients with R/M ACC. This study aimed to evaluate the therapeutic efficacy and safety of molecular-targeted agents in patients with R/M ACC and provide insights to guide clinical decision-making.

Material/Methods: